Advertisement


Martin H. Dreyling, MD, PhD, on Follicular Lymphoma: Safety and Efficacy of Tisagenlecleucel

EHA 2021 Virtual Congress

Advertisement

Martin H. Dreyling, MD, PhD, of University Hospital Munich Grosshadern Klinikum, discusses phase II results from the ELARA trial, which suggests tisagenlecleucel may be a promising immunotherapy for adults with relapsed or refractory follicular lymphoma (Abstract S210).



Related Videos

Lymphoma

Gaurav Goyal, MD, on DLBCL: Comparing R-CHOP and R-EPOCH for Overall Survival Benefits

Gaurav Goyal, MD, of the University of Alabama at Birmingham, reports on findings from a large multi-institutional database study, which showed there was no apparent difference in overall survival between R-CHOP and R-EPOCH among patients with advanced-stage MYC-rearranged, double-hit, or triple-hit diffuse large B-cell lymphoma. Further studies are needed for better risk stratification to optimize outcomes (Abstract S224).

Leukemia

Arnon P. Kater, MD, PhD, on CLL: Fixed-Duration Ibrutinib and Venetoclax vs Chlorambucil Plus Obinutuzumab

Arnon P. Kater, MD, PhD, of the University of Amsterdam, discusses a primary analysis of the phase III GLOW study, which, for the first time, compared the efficacy and safety of fixed-duration ibrutinib plus venetoclax with chlorambucil plus obinutuzumab for first-line treatment of older patients with chronic lymphocytic leukemia (LB1902).

Multiple Myeloma
Leukemia

Martin Kaiser, MD, on Myeloma and Plasma Cell Leukemia: Transplantation Plus Daratumumab/CVRD Therapy

Martin Kaiser, MD, of The Institute of Cancer Research and Royal Marsden Hospital, discusses findings from the UK OPTIMUM/MUKNINE trial on the depth of response and minimal residual disease status in patients with ultra-high–risk newly diagnosed multiple myeloma and plasma cell leukemia who were treated with augmented autologous transplant and daratumumab plus cyclophosphamide, bortezomib, lenalidomide, and dexamethasone (Abstract S181).

Leukemia

Keith W. Pratz, MD, on AML: Venetoclax, Azacitidine, and Disease Response

Keith W. Pratz, MD, of the University of Pennsylvania, discusses the outcomes of patients with acute myeloid leukemia who took part in the VIALE-A trial and were treated with venetoclax and azacitidine. The patients had achieved both composite complete remission and measurable residual disease of < 10-3 (Abstract S137).

Hematologic Malignancies
Immunotherapy

Efstathios Kastritis, MD, on Amyloidosis: Standard of Care Plus Daratumumab

Efstathios Kastritis, MD, of the University of Athens, discusses updated phase III results from the ANDROMEDA study of patients with newly diagnosed light chain amyloidosis. The trial further supports the use of daratumumab plus VCd (bortezomib, cyclophosphamide, and dexamethasone), which was shown to be clinically superior to VCd alone (Abstract S189).

Advertisement

Advertisement



Advertisement